- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT02638636
Internet-based Exposure-based Therapy for Fibromyalgia: A Randomized Controlled Trial.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Trial Objectives: Primary objective is to investigate whether an Internet-based exposure therapy can effectively reduce the degree of Fibromyalgia symptoms and impact. Secondary objectives are to 1) investigate the treatment's ability to reduce degree of a) quality of life b) function c) insomnia and fatigue d) pain-related fear and negative thoughts e) depression and anxiety, cost-effectiveness of this treatment; and 2) to study if any variables could moderate/mediate the treatment outcome, such as a) degree of covert avoidance, b) degree of reactivity to inner sensations
Trial Design: Randomized controlled trial with waitlist control, who also will receive treatment after the first group has finished.
Duration: Ten weeks
Primary Endpoint: Change in Fibromyalgia symptoms and impact from baseline to Week 10. Long term follow-up is also investigated (potential changes from post-treatment to 6- and 12 months after treatment completion)
Efficacy Parameters: the Fibromyalgia Impact Questionnaire (FIQ)
Description of Trial Subjects: Patients > 18 years old, Fibromyalgia diagnosis, residing in Sweden.
Number of Subjects: 140
Sample size estimation: Sample size is based on a estimated effect size (measured by Cohen's d) of 0.5, based on a power of 0.8 and with room for a 10 % dropout rate.
Recruitment: Self-referral. Advertising will be made through national newspaper, social media and on patient organisations' websites.
Safety parameters: Participants will have the opportunity to report any adverse events during treatment at posttreatment and follow-up measurements.
Data collection: Data will be collected electronically via the treatment platform.
Plan for missing data: Last-observation carried forward (LOCF).
Main statistical analysis: Hierarchical linear mixed modelling.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
Stockholm
-
Solna, Stockholm, Svezia, 17177
- Karolinska Institutet
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Fibromyalgia diagnosis
- Swedish resident
- Internet connection before, under and after treatment
- Willing to refrain from other concurrent psychological treatment during the study
- Agreement to keep psychotrophic medication constant during the study
Exclusion Criteria:
- Severe depression (≥30 points on Montgomery Åsberg Depression Rating Scale - Self Rated (MADRS-S) or risk of suicide (≥4 points on the suicide item on MADRS-S)
- Ongoing alcohol or substance abuse
- Psychosis
- Other severe illness that require immediate treatment and/or was considered the participants primary concern other than FM, or bodily condition that makes treatment unfeasible (such as late pregnancy; >29 weeks gestation
- Illiteracy or poor skills in Swedish language
- Insufficient computer or language skills to manage a text-based treatment.
- Other concurrent psychological treatment
- Recent changes in psychotrophic medication (<6 weeks prior to randomization)
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: Internet-based exposure therapy
The experimental group will go through active internet-based treatment which is delivered on a safe internet platform.
Treatment is divided into eight modules, each containing homework assignments.
Participants in experimental group will be assigned a therapist that they can contact through a message system in the platform and expect answer within 48 hours.
|
The treatment is a 10 week long cognitive behavior therapy.
It is based mainly on the principles of exposure; i.e. the participant is instructed to approach situations they have avoided in order to reduce or avoid pain or other aversive experiences until they feel less discomfort and extended behavior repertoire in presence of pain and aversive inner experiences Other interventions include psychoeducation, mindfulness and acceptance strategies and are employed in order to facilitate exposure.
|
Nessun intervento: Waitlist
Waitlist control, i.e. no active active intervention during waiting list period.
Will be offered treatment when the first group has finished (i.e.
week 10).
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Change in the Fibromyalgia Impact Questionnaire (FIQ)
Lasso di tempo: Week 0, week 10, Long term follow-up at 6- and 12-months after treatment has ended]
|
Change in Fibromyalgia symptoms and impact from baseline to Week 10, and at 6- and 12 months after treatment has ended.
|
Week 0, week 10, Long term follow-up at 6- and 12-months after treatment has ended]
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Insomnia Severity Index (ISI)
Lasso di tempo: Week 0, week 10, follow-up at 6- and 12-months after treatment has ended
|
Change in sleep disturbances from baseline to Week 10, and at 6- and 12 months after treatment has ended.
|
Week 0, week 10, follow-up at 6- and 12-months after treatment has ended
|
Fatigue Severity Scale (FSS)
Lasso di tempo: Week 0, week 10, follow-up at 6- and 12-months after treatment has ended
|
Change in fatigue from baseline to Week 10, and at 6- and 12 months after treatment has ended.
|
Week 0, week 10, follow-up at 6- and 12-months after treatment has ended
|
WHO Disability Assessment Schedule 2.0 (WHODAS 2)
Lasso di tempo: Week 0, week 10, follow-up at 6- and 12-months after treatment has ended
|
Change in level of function from baseline to Week 10, and at 6- and 12 months after treatment has ended.
|
Week 0, week 10, follow-up at 6- and 12-months after treatment has ended
|
Brunnsviken Brief Quality of Life Inventory (BBQ)
Lasso di tempo: Week 0, week 10, follow-up at 6- and 12-months after treatment has ended
|
Change in quality of life from baseline to Week 10, and at 6- and 12 months after treatment has ended.
|
Week 0, week 10, follow-up at 6- and 12-months after treatment has ended
|
The Psychological Inflexibility in Pain Scale (PIPS)
Lasso di tempo: Week 0, week 10, follow-up at 6- and 12-months after treatment has ended
|
Change in covert avoidance from baseline to Week 10, and at 6- and 12 months after treatment has ended.
|
Week 0, week 10, follow-up at 6- and 12-months after treatment has ended
|
Pain Reactivity Scale (PRS)
Lasso di tempo: Week 0, week 10, follow-up at 6- and 12-months after treatment has ended
|
Change in pain-related fear and negative thoughts from baseline to Week 10, and at 6- and 12 months after treatment has ended.
|
Week 0, week 10, follow-up at 6- and 12-months after treatment has ended
|
Patient Health Questionnaire-9 (PHQ-9)
Lasso di tempo: Week 0, week 10, follow-up at 6- and 12-months after treatment has ended
|
Change in level of depression from baseline to Week 10, and at 6- and 12 months after treatment has ended.
|
Week 0, week 10, follow-up at 6- and 12-months after treatment has ended
|
Generalised Anxiety Disorder 7-item scale (GAD-7)
Lasso di tempo: Week 0, week 10, follow-up at 6- and 12-months after treatment has ended
|
Change in level of anxiety from baseline to Week 10, and at 6- and 12 months after treatment has ended.
|
Week 0, week 10, follow-up at 6- and 12-months after treatment has ended
|
Subscale "reactivity to inner experiences" from Five Facets of Mindfulness Questionnaire (FFMQ)
Lasso di tempo: Week 0, week 10, follow-up at 6- and 12-months after treatment has ended
|
Change in reactivity to inner experiences from baseline to Week 10, and at 6- and 12 months after treatment has ended.
|
Week 0, week 10, follow-up at 6- and 12-months after treatment has ended
|
Trimbos and Institute of Medical Technology Assessment Cost Questionnaire for Psychiatry (TIC-P)
Lasso di tempo: Week 0, week 10, follow-up at 6- and 12-months after treatment has ended
|
Change in health-care costs and sick-leave from baseline to Week 10, and at 6- and 12 months after treatment has ended.
|
Week 0, week 10, follow-up at 6- and 12-months after treatment has ended
|
EQ5D
Lasso di tempo: Week 0, week 10, follow-up at 6- and 12-months after treatment has ended
|
Change in health-related quality of life from baseline to week 10, and at 6- and 12 months after treatment has ended.
|
Week 0, week 10, follow-up at 6- and 12-months after treatment has ended
|
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Item 9 from Montgomery Asberg Depression Rating Scale (MADRS-S)
Lasso di tempo: Week 1, week 2, week 3, week 4, week 5, week 6, week, 7, week 8, week 9
|
Possible presence of suicidal thoughts or ideation during treatment
|
Week 1, week 2, week 3, week 4, week 5, week 6, week, 7, week 8, week 9
|
Collaboratori e investigatori
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- EPN 2015/1528-31/1
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Internet-based exposure therapy
-
Ontario Shores Centre for Mental Health SciencesMindbeaconRitiratoDisturbo depressivo maggiore